Cost-effectiveness analysis of Sacituzumab Tirumotecan as second-line therapy for EGFR-TKI-resistant, EGFR-Mutated advanced NSCLC in China
{{output}}
Background: This study estimated the cost-effectiveness of sacituzumab tirumotecan (Sac-TMT) versus pemetrexed-platinum chemotherapy as second-line therapy for advanced EGFR-mutated non-small cell lung cancer (NSCLC) in China. ... ...
